Answers are grounded in this paper and cite their sources.
Retrospective study shows telemedicine with self-monitoring achieves glycemic targets safely in type 2 diabetes, indicating a cost-effective alternative to frequent clinic visits.
DTMS, based on telemedicine follow-up and multidisciplinary care with SMBG-based monitoring, appears to be safe and cost-effective in the intensive treatment of T2D without serious co-morbidities. This system also avoids limitations of a traditional health care such as the need for very frequent physical visits for each and every drug dose adjustment, diet, and exercise advice.
No takes yet. Share an insight, caveat, or question.
Kesavadev et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: